Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: A real-world study of 17 487 patients

European Journal of Gastroenterology and Hepatology

Volumn 29, Issue 6, 2017, Pages 686-693

  Su, Feng ^a   Beste, Lauren A ^a,b   Green, Pamela K ^a   Berry, Kristin ^a   Ioannou, George N ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

age; elderly; ledipasvir; paritaprevir ombitasvir ritonavir dasabuvir; sofosbuvir

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; VIRAL LOAD TESTING; AGE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GOVERNMENT; HEPACIVIRUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

AGE FACTORS; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; RETROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 85012883873     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000858     Document Type: Article

References (34)

1. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Centers for Disease C, Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61 (RR-4):1-32.
2. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263-270.
3. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777-782.
4. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521.
5. Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology 2015; 149:1471.e5-1482.e5.
6. Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, et al. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol 2014; 20:10984-10993.
7. Sato I, Shimbo T, Kawasaki Y, Mizokami M, Masaki N. Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: a retrospective study using the Japanese Interferon Database. Hepatol Res 2015; 45:829-386.
8. Tsui JI, Currie S, Shen H, Bini EJ, Brau N, Wright TL. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci 2008; 53:809-814.
9. El-Serag HB, Kramer J, Duan Z, Kanwal F. Epidemiology and outcomes of hepatitis C infection in elderly US veterans. J Viral Hepat 2016; 23: 687-696.
10. Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 2016; 151:457.e5-471.e5.
11. US Department of Veterans Affairs. Veterans affairs informatics and computing infrastructure. Available at: http://www.hsrd.research.va.gov/for-researchers/vinci/cdw.cfm. [Accessed 10 February 2016].
12. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39:106-111.
13. Yoshida EM, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015; 61:41-45.
14. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-36.
15. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008; 27:274-282.
16. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100:56-63.
17. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5:938-945.
18. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154:85-93.
19. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57: 249-257.
20. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106:483-491.
21. Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 2010; 8:972-978.
22. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47.
23. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140:1182.e1-1188. e1.
24. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 2004; 27 (Suppl 2):B10-B21.
25. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Investigators ION. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
26. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Investigators ION. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
27. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Investigators ION. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888.
28. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 2016; 63:1112-1119.
29. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
30. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-1603.
31. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-1614.
32. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
33. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877.
34. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62:932-954.